FDA Approves Bosutinib For Pediatric Patients With Chronic Myelogenous Leukemia; Also Approved A New Capsule Dosage Form Of Bosutinib Available In Strengths Of 50 Mg And 100 Mg
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Bosutinib, a drug for pediatric patients with chronic myelogenous leukemia. Additionally, a new capsule dosage form of Bosutinib is now available in strengths of 50 mg and 100 mg.
September 27, 2023 | 12:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pfizer's drug Bosutinib has been approved by the FDA for use in pediatric patients with chronic myelogenous leukemia. A new capsule dosage form is also available.
The FDA approval of Bosutinib for a new patient group and in a new dosage form expands the market for the drug, potentially increasing Pfizer's revenues. This is likely to have a positive impact on Pfizer's stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100